NRDN 201
Alternative Names: NRDN-201Latest Information Update: 05 Oct 2023
At a glance
- Originator Neurodon
- Class Antidementias; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Parkinson's disease
Most Recent Events
- 21 Oct 2022 Preclinical trials in Alzheimer's disease in USA (unspecified route) (Neurodon pipeline, October 2022)
- 21 Oct 2022 Preclinical trials in Parkinson's disease in USA (unspecified route) (Neurodon pipeline, October 2022)
- 21 Oct 2022 Pharmacodynamics data from preclinical study in Parkinson’s disease released by Neurodon (Neurodon pipeline, October 2022)